68 related articles for article (PubMed ID: 20850175)
21. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
Simchoni S; Friedman E; Kaufman B; Gershoni-Baruch R; Orr-Urtreger A; Kedar-Barnes I; Shiri-Sverdlov R; Dagan E; Tsabari S; Shohat M; Catane R; King MC; Lahad A; Levy-Lahad E
Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3770-4. PubMed ID: 16537453
[TBL] [Abstract][Full Text] [Related]
22. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.
Oddoux C; Struewing JP; Clayton CM; Neuhausen S; Brody LC; Kaback M; Haas B; Norton L; Borgen P; Jhanwar S; Goldgar D; Ostrer H; Offit K
Nat Genet; 1996 Oct; 14(2):188-90. PubMed ID: 8841192
[TBL] [Abstract][Full Text] [Related]
23. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
King MC; Marks JH; Mandell JB;
Science; 2003 Oct; 302(5645):643-6. PubMed ID: 14576434
[TBL] [Abstract][Full Text] [Related]
24. Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer.
Schorge JO; Mahoney NM; Miller DS; Coleman RL; Muller CY; Euhus DM; Tomlinson GE
Gynecol Oncol; 2001 Nov; 83(2):383-7. PubMed ID: 11606101
[TBL] [Abstract][Full Text] [Related]
25. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.
Lavie O; Hornreich G; Ben-Arie A; Rennert G; Cohen Y; Keidar R; Sagi S; Lahad EL; Auslander R; Beller U
Gynecol Oncol; 2004 Feb; 92(2):521-4. PubMed ID: 14766242
[TBL] [Abstract][Full Text] [Related]
26. Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients.
Manguoglu AE; Lüleci G; Ozçelik T; Colak T; Schayek H; Akaydin M; Friedman E
Hum Mutat; 2003 Apr; 21(4):444-5. PubMed ID: 12655560
[TBL] [Abstract][Full Text] [Related]
27. The founder Ashkenazi Jewish mutations in the MSH2 and MSH6 genes in Israeli patients with gastric and pancreatic cancer.
Laitman Y; Herskovitz L; Golan T; Kaufman B; Paluch SS; Friedman E
Fam Cancer; 2012 Jun; 11(2):243-7. PubMed ID: 22219001
[TBL] [Abstract][Full Text] [Related]
28. A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families.
Phelan CM; Kwan E; Jack E; Li S; Morgan C; Aubé J; Hanna D; Narod SA
Hum Mutat; 2002 Nov; 20(5):352-7. PubMed ID: 12402332
[TBL] [Abstract][Full Text] [Related]
29. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
30. Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers.
Sade RB; Chetrit A; Figer A; Papa MZ; Flex D; Rizel S; Friedman E
Eur J Cancer; 2006 Mar; 42(5):650-5. PubMed ID: 16464572
[TBL] [Abstract][Full Text] [Related]
31. The frequency of the predominant Jewish mutations in BRCA1 and BRCA2 in unselected Ashkenazi colorectal cancer patients.
Chen-Shtoyerman R; Figer A; Fidder HH; Rath P; Yeremin L; Bar Meir S; Friedman E; Theodor L
Br J Cancer; 2001 Feb; 84(4):475-7. PubMed ID: 11207040
[TBL] [Abstract][Full Text] [Related]
32. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.
Lancaster JM; Powell CB; Kauff ND; Cass I; Chen LM; Lu KH; Mutch DG; Berchuck A; Karlan BY; Herzog TJ;
Gynecol Oncol; 2007 Nov; 107(2):159-62. PubMed ID: 17950381
[TBL] [Abstract][Full Text] [Related]
33. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME
Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693
[TBL] [Abstract][Full Text] [Related]
34. Cancer genetics and reproduction.
Hanson H; Hodgson S
Best Pract Res Clin Obstet Gynaecol; 2010 Feb; 24(1):3-18. PubMed ID: 19864186
[TBL] [Abstract][Full Text] [Related]
35. [Hereditary predispositions to gynaecological cancers].
Coupier I; Pujol P
Gynecol Obstet Fertil; 2005 Nov; 33(11):851-6. PubMed ID: 16256400
[TBL] [Abstract][Full Text] [Related]
36. High risk of colorectal and endometrial cancer in Ashkenazi families with the MSH2 A636P founder mutation.
Mukherjee B; Rennert G; Ahn J; Dishon S; Lejbkowicz F; Rennert HS; Shiovitz S; Moreno V; Gruber SB
Gastroenterology; 2011 Jun; 140(7):1919-26. PubMed ID: 21419771
[TBL] [Abstract][Full Text] [Related]
37. Changing patterns of referrals and outcomes of genetic participation in gynaecological-oncology multidisciplinary care.
Pokharel HP; Hacker NF; Andrews L
Aust N Z J Obstet Gynaecol; 2016 Dec; 56(6):633-638. PubMed ID: 27530527
[TBL] [Abstract][Full Text] [Related]
38. Hereditary cancer screening: Case reports and review of literature on ten Ashkenazi Jewish founder mutations.
Cox DM; Nelson KL; Clytone M; Collins DL
Mol Genet Genomic Med; 2018 Nov; 6(6):1236-1242. PubMed ID: 30152102
[TBL] [Abstract][Full Text] [Related]
39. Hereditary gynaecological malignancies: advances in screening and treatment.
Folkins AK; Longacre TA
Histopathology; 2013 Jan; 62(1):2-30. PubMed ID: 23240667
[TBL] [Abstract][Full Text] [Related]
40. Characterization of two Ashkenazi Jewish founder mutations in MSH6 gene causing Lynch syndrome.
Raskin L; Schwenter F; Freytsis M; Tischkowitz M; Wong N; Chong G; Narod SA; Levine DA; Bogomolniy F; Aronson M; Thibodeau SN; Hunt KS; Rennert G; Gallinger S; Gruber SB; Foulkes WD
Clin Genet; 2011 Jun; 79(6):512-22. PubMed ID: 21155762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
